OPTIMED TECHNOLOGY, INC.

Description

The Arany Lab, Department of Oral Biology and Biomedical Engineering, University at Buffalo and OptiMed Technology, Inc. has developed a novel approach to improve oral-dental health that is currently a 14 billion dollar market. A novel formulation with polymeric microspheres has been developed to address a condition termed Drug-Induced Gingival Overgrowth (DIGO) that is caused by side-effects of commonly used medications for high blood pressure, convulsions, and organ transplants. This disease affects over 20 million patients in the U.S currently. The commercialization of these formulations is currently underway.

Contact

Derek Cadwallader
0

View More Awardee Profiles

Exhibitor Inquiry
Attendee Request Form: 2023 Hardware Prototyping Workshop
Thanks for your interest in this resource, fill out the information below to download.

"*" indicates required fields

Hidden
This field is for validation purposes and should be left unchanged.

X
X